Ganciclovir
Product Images NDC 51754-2500

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 51754-2500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exela Pharma Sciences, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance Formulas (Spl Image1 Formula)

This panel shows equations for calculating creatinine clearance for males and females. The formula for males involves age, body weight, and serum creatinine concentration, while the female value is 0.85 times the male value. This is part of clinical or pharmacokinetic guidance information.*

FDA Label Image

Structure (Spl Image2 Structure)

Chemical structure of ganciclovir, showing the molecular arrangement including a purine base connected to a side chain with multiple hydroxyl groups.*

FDA Label Image

Figure 1 (Spl Image3 Figure1)

A line graph titled "ICM 1653: Time to Progression of CMV Retinitis" showing the proportion of patients without progression over time from the start of maintenance therapy in days. It compares two lines representing IV and Oral routes, depicting a decline in progression-free proportion over 150 days.*

FDA Label Image

Figure 2 (Spl Image4 Figure2)

A line chart titled 'ICM 1774: Time to Progression of CMV Retinitis' showing the proportion of patients without disease progression over time. The x-axis represents time from the start of maintenance therapy in days (0 to 120), and the y-axis shows the proportion without progression (0 to 1.0). Two treatment groups are compared: intravenous (IV) with a dashed line and oral with a solid line, with IV showing a slower progression over time.*

FDA Label Image

Figure 3 (Spl Image5 Figure3)

A line graph titled 'AVI 034: Time to Progression of CMV Retinitis' showing proportion without progression on the y-axis and time from start of maintenance therapy in days on the x-axis. Two lines compare IV and oral treatment methods over approximately 150 days, illustrating decreasing proportions without progression over time.*

FDA Label Image

Container Label Bag (Spl Image6 Label Bag 500mg)

Ganciclovir Injection 500 mg per 250 mL (2 mg per mL) in a 250 mL intravenous infusion bag. The label indicates a 0.8% sodium chloride solution, single-dose use with instructions to discard unused portions. Manufactured and distributed by Exela Pharma Sciences, LLC. The label includes storage, dosage, and caution information, with barcode and recycling symbols visible.*

FDA Label Image

Label Overwrap (Spl Image7 Label Overwrap 500mg)

Ganciclovir Injection 500 mg per 250 mL (2 mg per mL) single-dose container. The 250 mL bag contains 2 mg/mL ganciclovir, 8 mg sodium chloride, and may include sodium hydroxide and hydrochloric acid to adjust pH to 7.5. Manufactured and distributed by Exela Pharma Sciences, LLC. Label includes dosage, caution, and storage instructions, plus a barcode and recycling symbol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.